Literature DB >> 1492418

Comparative biodisposition and metabolism of 14C-(+/-)-fenfluramine in mouse, rat, dog and man.

N C Marchant1, M A Breen, D Wallace, S Bass, A R Taylor, R M Ings, D B Campbell, J Williams.   

Abstract

1. The comparative metabolism of fenfluramine was investigated in mouse, rat, dog and man following a single oral dose of 14C-(+/-)-fenfluramine hydrochloride (1 mg/kg), and also in rat after eight consecutive 12-h subcutaneous doses (24 mg/kg). 2. Main route of excretion of radioactivity in all species and at all doses was into urine (> 80%), with only minor amounts of radioactivity found in faeces. 3. From all species examined a total of 11 metabolites were observed in urine and plasma by t.l.c. and h.p.l.c. analysis and no metabolite was present in the plasma which was not present in urine. 4. All species dealkylate fenfluramine to the active metabolite norfenfluramine, to a relative greater or lesser extent, with plasma metabolic ratios (norfenfluramine/fenfluramine) showing inter-animal variation (rat >> dog >> mouse = man). 5. These differences are due to the efficient deamination of both compounds to polar inactive metabolites in man, with less dealkylation and lower plasma levels of norfenfluramine compared with the other species studied. 6. In conclusion, major species differences in the metabolism of (+/-)-fenfluramine, both qualitative and quantitative were observed, and no one species had a similar metabolic profile to that found in man.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1492418     DOI: 10.3109/00498259209053154

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  9 in total

Review 1.  Appetite suppressants, cardiac valve disease and combination pharmacotherapy.

Authors:  Richard B Rothman; Michael H Baumann
Journal:  Am J Ther       Date:  2009 Jul-Aug       Impact factor: 2.688

Review 2.  The use of toxicokinetics for the safety assessment of drugs acting in the brain.

Authors:  D B Campbell
Journal:  Mol Neurobiol       Date:  1995 Aug-Dec       Impact factor: 5.590

Review 3.  Dexfenfluramine. An updated review of its therapeutic use in the management of obesity.

Authors:  R Davis; D Faulds
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

Review 4.  In vitro evaluation suggests fenfluramine and norfenfluramine are unlikely to act as perpetrators of drug interactions.

Authors:  Parthena Martin; Maciej Czerwiński; Pallavi B Limaye; Brian W Ogilvie; Steven Smith; Brooks Boyd
Journal:  Pharmacol Res Perspect       Date:  2022-06

Review 5.  In vitro evaluation of fenfluramine and norfenfluramine as victims of drug interactions.

Authors:  Parthena Martin; Maciej Czerwiński; Pallavi B Limaye; Seema Muranjan; Brian W Ogilvie; Steven Smith; Brooks Boyd
Journal:  Pharmacol Res Perspect       Date:  2022-06

6.  Reduced hypophagic effects of d-fenfluramine and the 5-HT2C receptor agonist mCPP in 5-HT1B receptor knockout mice.

Authors:  Michelle D Lee; Elizabeth M Somerville; Guy A Kennett; Colin T Dourish; Peter G Clifton
Journal:  Psychopharmacology (Berl)       Date:  2004-05-08       Impact factor: 4.530

7.  Effect of d-fenfluramine on the indole contents of the rat brain after treatment with different inducers of cytochrome P450 isoenzymes.

Authors:  M Anelli; C Fracasso; A Bergami; A Ferrarese; S Garattini; S Caccia
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

Review 8.  Serotonergic drugs and valvular heart disease.

Authors:  Richard B Rothman; Michael H Baumann
Journal:  Expert Opin Drug Saf       Date:  2009-05       Impact factor: 4.250

9.  Efficacy of Fenfluramine and Norfenfluramine Enantiomers and Various Antiepileptic Drugs in a Zebrafish Model of Dravet Syndrome.

Authors:  Jing Li; Maxim Nelis; Jo Sourbron; Daniëlle Copmans; Lieven Lagae; Deirdre Cabooter; Peter A M de Witte
Journal:  Neurochem Res       Date:  2021-05-26       Impact factor: 3.996

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.